Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.30M | 4.78M | 8.30M | 2.47M | 3.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.10M | 15.96M | 16.16M | 6.88M | 8.26M |
| Operating Income | -18.10M | -15.96M | -16.16M | -6.88M | -8.26M |
| Income Before Tax | -14.46M | -12.64M | -16.71M | -6.37M | -8.74M |
| Income Tax Expenses | 30.40K | 13.90K | 11.30K | -600.00 | 5.60K |
| Earnings from Continuing Operations | -14.49M | -12.65M | -16.72M | -6.37M | -8.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 6.50K | 1.40K | 10.10K | 8.00K | 6.80K |
| Net Income | -14.49M | -12.65M | -16.71M | -6.36M | -8.74M |
| EBIT | -18.10M | -15.96M | -16.16M | -6.88M | -8.26M |
| EBITDA | -18.02M | -15.90M | -16.11M | -6.84M | -8.23M |
| EPS Basic | -0.23 | -0.23 | -0.34 | -0.19 | -0.26 |
| Normalized Basic EPS | -0.14 | -0.14 | -0.20 | -0.11 | -0.15 |
| EPS Diluted | -0.23 | -0.23 | -0.34 | -0.19 | -0.26 |
| Normalized Diluted EPS | -0.14 | -0.14 | -0.20 | -0.11 | -0.15 |
| Average Basic Shares Outstanding | 66.22M | 56.71M | 51.30M | 36.92M | 35.91M |
| Average Diluted Shares Outstanding | 66.22M | 56.71M | 51.30M | 36.92M | 35.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |